Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for CALQUENCE
- Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
- Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
- Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
- A Prospective, Open-label, Multicentre, Randomized, Phase-3-trial of Acalabrutinib, Obinutuzumab and Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk Chronic Lymphatic Leukemia
- ACALA-R In Anti-MAG Neuropathy Mediated Neuropathy
- Preventing Anaphylaxis With Acalabrutinib
- Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
- Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Acalabrutinib in CNSL
- Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
- Avo In R/R And Previously Untreated MCL
- Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
- Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
- Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule
- Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
- Early Intervention With Acalabrutinib in Patients With High Risk CLL
- Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
- Study of Acalabrutinib and Tafasitamab in MZL Patients
- Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
- Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
- AU2 In Relapsed and Untreated CLL
- Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
- LCCC1841: A Phase 2 Trial of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
- Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
- Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19
- Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
- Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
- Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
- Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
- Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease
- Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma
- Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
- Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
- Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment
- Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
- Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL
- Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
- Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Clinical trials list
click for details